Kneat Announces Selection by Top Ten Biopharma as the Corporate Solution for Global Manufacturing and Provides an Update on its Recent Financing
News provided by
Share this article
LIMERICK, Ireland, May 7, 2021 /CNW/ -
kneat.com, inc. (TSX-V: KSI) ("Kneat") announces it has signed a five-year corporate Master Services Agreement (MSA) with another top ten biopharma company, and provides an update on its recent financing.
Top Ten Biopharma Selects Kneat as its Corporate Validation Platform for Global Manufacturing
In December 2020, Kneat announced its SaaS platform was chosen by this research and development-focused biopharma leader for a single site. Today, we are pleased to announce it has selected Kneat as its corporate-wide manufacturing e-Validation platform. The company has more than seventy thousand employees across multiple operations in six continents, and the selection of Kneat follows an extensive formal evaluation by the company's digital manufacturing solutions team. This agreement, which is effective immediately, allows the company and its Affiliates to deploy Kneat across all their manufacturing sites, representing a considerable opportunity for the expansion of SaaS licenses over the coming years.